Comprehensive genomic profiling (CGP) is now standard of care in advanced cancer — guideline-backed, reimbursed, and tied to better outcomes. Yet adoption stalls at the point of testing.
Tissue ships to a handful of national labs; your system loses control of the workflow.
2–3 week TAT delays therapy decisions in patients who can't wait.
Most hospitals lack in-house bioinformatics and molecular pathology to test locally.
Your system captures little of the value, so testing never gets prioritized.
The bottleneck isn't the science. It's access, speed, expertise, and alignment.
We place testing inside your hospital and run the hard parts with agentic AI — expanding access, improving the clinical experience, and sharing the economics with your system.
An agentic dry lab democratizes the bioinformatics and molecular-pathology expertise hospitals lack — so any qualified lab can run clinical-grade CGP.
In-house testing cuts turnaround from weeks to days and enables deeper personalization — therapy selection, monitoring, and care-pathway support.
A shared payment model lets your system keep real margin and a share of downstream data value — so testing finally gets prioritized.
Tasks that once required scarce specialists can now be done by AI agents, end to end:
Regulatory-cleared sequencing is moving testing out of reference labs and into local hands:
Agentic AI supplies the expertise; approved kits supply the assay. Together they make in-hospital testing finally viable.
Placed at zero capital cost. Start with NextSeq 550Dx + TSO Comprehensive; add MRD on the same instrument; expand to new kits and platforms over time.
AI agents run bioinformatics and interpretation, giving any qualified lab the analytical horsepower of a national reference lab.
Sequence to signed report — automated QC, annotation, and molecular-pathology sign-out delivered as a clinical-grade report.
Revenue-cycle services that handle coding and reimbursement, so the hospital captures the economics without the overhead.
Testing is the foundation. With patient consent, the same genomic + clinical data opens new sources of value for your system.
the foundation everything builds on.
De-identified records licensed to biopharma — your system shares in a recurring revenue stream.
Trial access for your patients today; co-development of new diagnostics tomorrow.
Longitudinal data feeds monitoring, therapy selection, and care pathways back to your clinicians.
Send tissue to a reference lab and the reimbursement and data value go with it. Bringing testing in-house keeps both inside your system.
Tissue ships to Foundation Medicine, Tempus, Caris
Testing runs inside your system
Same test, same patients — but the operational control, economics and data stay with you.
A short discovery session with your clinical and operational leaders to map current testing volumes, gaps, and goals.
We review your lab, case mix, and EHR environment to size the opportunity and design the right configuration — no commitment required.
Together we scope a focused pilot — timeline, success metrics, and support — so your team can see the model work before scaling.
A short discovery session is the simplest way to see how the model fits your system. No capital cost, no commitment.